Drugs / GSK4771261
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07600450 | May → Sep 2026 overdue | kidney disorder | GlaxoSmithKline | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06734234 | Dec 2024 → Apr 2027 expected | kidney disorder | GlaxoSmithKline | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK4771261 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06734234 ↗ |
| Route | Subcutaneous | “Administered as a Single Subcutaneous Dose” NCT07600450 ↗ |